L
oss of functional cardiomyocytes by cell death has been implicated in ischemic myocardial injury, pathological cardiac remodeling, and heart failure. Although apoptosis has been well established as a highly regulated form of cell death, necrosis was thought to be an unregulated, passive form of cell death caused by overwhelming physicochemical stress. Recent advances identified a regulated type of necrosis termed programmed necrosis or necroptosis. 1 Induction of necroptosis requires the activation of receptor-interacting proteins 1 and 3 (RIP1 and RIP3), which form the necroptotic cell death complex termed necrosome. [2] [3] [4] The activated necrosome then engages mixed lineage kinase domainlike protein (MLKL) through RIP3-dependent phosphorylation. Phosphorylated MLKL oligomerizes and binds to phospholipids to disrupt membrane integrity, resulting in necroptotic cell death. 5, 6 Necroptosis has been implicated in a number of pathological conditions, such as ischemic injury, neurodegenerative diseases, viral infection, and inflammation. However, the regulation and significance of necroptosis in the heart remain poorly understood. Moreover, whether and how necroptosis can be targeted for the treatment of myocardial remodeling and heart failure has not been investigated.
Apoptosis and necroptosis are induced by specific death receptors, such as tumor necrosis factor receptor 1 (TNFR1), among other modules. The pleiotropic nature of TNFR1 signaling results from the formation of different signaling complexes. 7, 8 Under normal conditions, ligation of TNFR1 induces the assembly of a plasma membrane bound signaling complex, termed complex I, which contains TNFR-associated protein with death domain (TRADD), TNFR-associated protein 2 (Traf2), receptor-interacting protein 1 (RIP1), and cellular inhibitor of apoptosis proteins 1 and 2 (cIAP1 and cIAP2). 9 The recruitment of transforming growth factor β-activated kinase 1 (TAK1) and the IκB kinase complex to complex I leads to the activation of NFκB. Under cell death-inducing conditions, the TNFR1 complex internalizes and converts to a cell death-inducing complex, termed complex II, with additional recruitment of Fas-associated protein with death domain (FADD) and caspase 8.
9 TNFR1 signaling can also induce the necroptotic cell death complex, termed necrosome, consisting of RIP1, RIP3, and FADD, which often occurs when apoptosis is blocked. 10 Traf2 is a key component of the TNFR1 signaling complex, which is recruited to TNFR1 by interacting with the adaptor protein TRADD. 11 Like other TRAF proteins, Traf2 has a conserved TRAF-C domain, a coiled coil TRAF-N domain, and an N-terminal RING E3 ubiquitin ligase domain. 12 Traf2 plays a pivotal role in transducing signals from receptors of the TNFR superfamily and the interleukin-1/Toll-like receptor superfamily, regulating cell proliferation, inflammation, immune response, and cell survival and apoptosis. In addition to transducing TNFα-induced NFκB activation, Traf2 can regulate apoptotic cell death independent of its role in NFκB activation, 13 but the effector mechanisms remain unclear. Traf2 also mediates mitochondrial autophagy, which confers protection against hypoxia/reoxygenation injury in cardiomyocytes. 14 Recent studies indicate that Traf2 plays a role in necroptotic cell death induced by several death ligands, including TNFα, Apo2L/TRAIL, and Fas/CD95L. 15, 16 However, the molecular mechanisms by which Traf2 regulates necroptosis remain elusive.
Genetic deletion of Traf2 in mice led to early lethality with severe developmental and immune defects and increased cellular sensitivity to TNFα killing. 17 It has been shown that mice with cardiac-restricted expression of low levels of Traf2 were protected against ischemia-reperfusion injury. 18 However, transgenic mice expressing high levels of Traf2 developed adverse remodeling and heart failure. 19 The necessary role of Traf2 in myocardial survival and cardiac homeostasis has not been investigated by a loss-of-function approach. In this study, we identified a critical role for Traf2 in myocardial survival and homeostasis by suppressing both apoptosis and necroptosis, independent of the NFκB signaling. Cardiac-specific deletion of Traf2 in mice promoted apoptotic and necroptotic cardiac cell death, which led to pathological remodeling and heart failure. We also provide genetic evidence that ablation of TNFR1 or RIP3 largely rescued the pathological phenotype associated with Traf2 deficiency in vivo, revealing a crucial role of the TNFR1-mediated, RIP3-dependent necroptotic signaling pathway in the heart.
Clinical Perspective
What Is New?
• This study identified an important tumor necrosis factor receptor-associated factor 2-mediated, NFκB-independent, prosurvival pathway in the heart by suppressing apoptosis and necroptosis.
• This study defined novel molecular mechanisms whereby tumor necrosis factor receptor-associated factor 2 suppresses tumor necrosis factor receptor 1-mediated, receptor-interacting protein 3-dependent necroptosis, which is critical for myocardial survival and homeostasis.
What Are the Clinical Implications?
• These findings suggest that the necroptosis-suppressing tumor necrosis factor receptor-associated factor 2 signaling pathway and its effectors may serve as novel therapeutic targets for pathological cardiac remodeling and heart failure.
Cell Culture, Adenoviral and Lentiviral Vectors, and Cell Death Analysis
Primary neonatal rat cardiomyocytes were prepared from hearts of 1-to 2-day-old Sprague-Dawley rat pups as previously described. 23, 24 Traf2 +/+ and Traf2 -/-mouse embryonic fibroblasts (MEFs) were from Tak Mak (University Health Network). Adβgal and AdTAK1-ΔN have been described previously. 26 Adenoviruses encoding mouse Traf2 were generated using the ViraPower Adenoviral Expression System (Invitrogen). Lentiviral particles encoding shRNA sequences for specific target genes were obtained from Sigma. Cell death was measured as previously described.
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Statistics
Sample size was estimated before performing the study based on our previous experience with similar studies or by conducting pilot experiments to estimate effect size followed by power analysis (α=0.05; power=80%). Results are presented as mean±SEM. Mann-Whitney U-test or KruskalWallis test followed by post hoc Mann-Whitney U-test with Bonferroni's correction was used for studies with small sample sizes. Some data were analyzed by Friedman test followed by pairwise comparisons with post hoc Wilcoxon signed-rank test. Data groups with normal distribution were evaluated by 1-way analysis of variance with the Bonferroni's post hoc test. P<0.05 was considered statistically significant.
RESULTS
Loss of Traf2 in the Heart Induces Cardiomyocyte Death, Pathological Cardiac Remodeling, and Dysfunction
To assess the role of Traf2 in the heart, we first examined cardiac Traf2 expression after pathological stress. Traf2 expression was markedly increased in the mouse heart subjected to TAC and MI injury for 2 weeks (Figure 1A and 1B) , suggesting a potential role of Traf2 in myocardial response to pathological stress. To study the function of Traf2 in the heart in vivo, we generated mice with cardiomyocyte-specific deletion of Traf2. Mice homozygous for the Traf2-loxp (fl)-targeted allele (Traf2fl/fl) 20 were crossed with cardiomyocytespecific Cre lines, including α-myosin heavy chain α-MHC-Cre 21 and β-MHC-Cre. 22 Western blot analysis showed efficient deletion of Traf2 (>90%) in the heart from the Traf2fl/fl-αMHC-Cre mice ( Figure 1C ). Histological analysis of cardiac sections of Traf2fl/fl-αMHC-Cre mice revealed high levels of myocardial fibrosis and cardiomyocyte dropout ( Figure 1D ). A significant increase in TUNEL-positive cells was also detected in Traf2-deficient mice ( Figure 1E ). Consistent with this finding, Western blot analysis showed increased poly ADP-ribose polymerase cleavage and upregulated Bax expression in the Traf2-deficient heart compared with Traf2fl/fl controls, indicating increased apoptosis (Figure 1F) . It is important to note that increased plasma levels of HMGB1 ( Figure 1G ), a new biomarker for necrotic cell death and myocardial infarction, 27, 28 was also detected in Traf2-deficient mice. Therefore, loss of Traf2 promoted apoptotic and necrotic cardiac cell death in vivo, suggesting an essential role for Traf2 in myocardial survival and homeostasis.
Traf2fl/fl-αMHC-Cre mice developed significant cardiac dysfunction, ventricular dilation, and cardiac hypertrophy compared with the littermate controls ( Figure 1H These results indicate that ablation of Traf2 promotes pathological cardiac remodeling and dysfunction, further suggesting a protective role of Traf2 in the heart.
We further investigated the role of Traf2 in regulating myocardial remodeling and heart failure propensity after pathological stimulation. Here we used mice heterozygous for Traf2-loxP allele with αMHC-Cre (Traf2fl/+αCre) to evaluate the role of Traf2 in MIinduced pathological remodeling and heart failure. In contrast to the Traf2fl/fl-αCre mice, Traf2fl/+αCre mice were overtly normal at baseline, with no signs of cardiac dysfunction ( Figure III in the online-only Data Supplement). However, Traf2fl/+αCre mice showed a greater propensity for cardiac dysfunction and ventricular dilation after MI, which was associated with elevated myocardial cell death assessed by TUNEL staining and plasma HMGB1 levels ( Figure III in the online-only Data Supplement). An increase in infarct size and cTnI plasma levels was also detected after acute MI for 24 hours ( Figure III in the online-only Data Supplement). Thus, reduced Traf2 expression predisposed mice to cardiac dysfunction and failure after MI, suggesting a critical cardioprotective role for Traf2 in response to pathological stress.
Ablation of TNFR1 Prevents the Pathological Cardiac Remodeling and Dysfunction in Traf2-Deficient Mice
TNFR1 is an important death receptor that has been implicated in the pathogenesis of myocardial remodeling and heart failure. 29 Traf2 can be recruited to the TNFR1 to form the complex I and activates downstream signaling. 11 Here we detected a significant increase in the plasma level of TNFα in Traf2-deficient mice (Figure 2A ). These observations prompted us to investigate the role of TNFR1-mediated cell death pathway in pathological remodeling and heart failure in Traf2-deficient mice. To explore this idea, we crossed Tnfrsf1a of adverse cardiac remodeling and dysfunction triggered by Traf2 deficiency.
Traf2 Is a Nodal Regulator of Apoptotic and Necrotic Cell Death
Based on data presented previously, we hypothesized that deletion of Traf2 triggers adverse cardiac remodeling and heart failure by promoting TNFα-mediated cell death signaling. Indeed, deletion of Traf2 in MEFs induced rapid cell death with propidium iodide uptake after TNFα stimulation ( Figure 3A ). This effect was largely blocked by the RIP1 inhibitor necrostatin-1 30 but not by the pancaspase inhibitor z-Vad-fmk (zVad), suggesting the induction of necroptosis. Moreover, HMGB1, a biomarker for necrosis, was released into the culture supernatants of One-way analysis of variance with Bonferroni's post hoc test was used in A, C, D, and F. Data were from ≥3 independent experiments with ≥900 cells per group analyzed for cell death. All immunoblot data represent ≥3 independent experiments with similar results. GAPDH indicates Glyceraldehyde 3-phosphate dehydrogenas; HMGB1, high-mobility group box 1; MEF, mouse embryonic fibroblast; MLKL, mixed lineage kinase domain-like protein; PARP, poly ADP-ribose polymerase; RIP, receptor-interacting protein; sup, supernatant; TAK1, transforming growth factor β-activated kinase 1; TNF, tumor necrosis factor; and Traf2, TNF receptor-associated factor 2.
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-/-MEFs after TNFα stimulation, which was further increased by the addition of zVad ( Figure 3B ). Deletion of Traf2 also promoted TNFα-induced poly ADP-ribose polymerase cleavage and caspase 8 activation, an effect that was reversed by both necrostatin-1and zVad ( Figures 3B  and 3C ). These results indicate that inhibition of Traf2 promotes apoptotic and necroptotic signaling through the activation of RIP1 and caspases. Next, we examined whether Traf2 regulates apoptosis and necroptosis in cardiomyocytes by silencing Traf2 with an adenoviral vector.
Consistent with the results in Traf2
-/-MEFs, ablation of Traf2 similarly promoted TNFα-induced apoptosis and necroptosis in cardiomyocytes (Figures 3D and 3E) .
To further examine the regulatory role of Traf2 in necroptosis, cardiomyocytes were infected with an adenovirus encoding wild-type Traf2 (Ad-Traf2), a dominantnegative Traf2 mutant lacking the RING E3 ubiquitin ligase domain (Ad-Traf2ΔR) or a control β-galactosidase adenovirus (Ad-βgal), followed by TNFα stimulation. Overexpression of wild-type Traf2 suppressed necroptotic cell death as well as HMGB1 release induced by TNFα plus zVad ( Figure 3F and 3G) . In contrast, overexpression of Traf2ΔR promoted TNFα-induced necroptosis, which was blocked by necrostatin-1 but augmented by zVad ( Figure 3F and 3G) . Thus, the RING E3 ubiquitin ligase domain of Traf2 plays a critical role in cell survival and necroptosis inhibition, probably through ubiquitination of key necroptosis signaling proteins such as TAK1 and RIP1.
Traf2 has been shown to mediate TNFα-induced NFκB activation, a transcription factor that drives the expression of prosurvival genes. However, consistent with previous studies, 31, 32 we observed that deletion of Traf2 in MEFs or overexpression of Traf2ΔR in cardiomyocytes had minimal effects on TNFα-induced NFκB activation, as assessed by phosphorylation and degradation of IκB ( Figure 
Traf2 Regulates Necroptotic Cell Death Signaling Through TAK1 and TRADD
To investigate the underlying mechanisms, we examined the role of several key components of TNFR1 signaling pathway in necroptotic cell death triggered by Traf2 inhibition. The adapter protein TRADD mediates the recruitment of Traf2 to TNFR1, which is critical for the induction of downstream signaling complexes. 11 However, the role of TRADD in necroptotic signaling remains unclear. Cardiomyocytes were infected with adenoviral vectors encoding TRADD shRNA (Ad-shTRADD) or a scrambled sequence (Ad-shScram) along with Adβgal or AdTraf2ΔR, followed by stimulation with TNFα plus zVad. Ablation of TRADD largely blocked necroptotic cell death and HMGB1 release induced by TNFα plus zVad in Ad-Traf2ΔR-infected cells ( Figure 4A and 4B) . In addition, knockdown of TRADD also largely abrogated the RIP1-RIP3 necrosome formation ( Figure 4C ). Therefore, these data indicate an indispensable role for the adaptor protein TRADD in necroptotic signaling upstream of Traf2.
Traf2 has been shown to critically regulate polyubiquitination and activation of TAK1, [34] [35] [36] an important regulator of necroptosis. 23 To determine whether TAK1 acts as an effector downstream of Traf2 in necroptotic signaling, we examined whether forced activation could affect necroptotic signaling in Traf2-deficient cells. Cardiomyocytes were infected with an adenovirus encoding a constitutively active TAK1 mutant (Ad-TAK1ΔN) in the presence or absence of AdTraf2ΔR, followed by stimulation with TNFα and zVad. Indeed, TAK1ΔN overexpression largely blocked necroptotic cell death and HMGB1 release induced by TNFα plus zVad in AdTraf2ΔR-infected cells ( Figure 4D and 4E ). TAK1ΔN overexpression was associated with autophosphorylation on Thr187, indicating kinase activation. 26 Forced activation of TAK1 also inhibited the necrosome formation by inhibiting RIP1-RIP3-FADD interaction ( Figure 4F ). Therefore, TAK1 activation is sufficient to inhibit necroptotic signaling triggered by Traf2 inhibition, suggesting that TAK1 may act downstream of Traf2 in necroptotic signaling.
Cylindromatosis (CYLD) is a deubiquitinating enzyme that has been shown to counteract with the effect of Traf2 in regulating protein ubiquitination, such as TAK1 and RIP1. 35, 37 To examine whether and how CYLD affects necroptotic signaling triggered by Traf2 inhibition, cardiomyocytes were infected with an adenovirus expressing CYLD shRNA in the presence or absence of AdTraf2ΔR, followed by stimulation with TNFα and zVad. Ablation of CYLD had no significant effect on necroptotic cell death or HMGB1 release induced by Traf2 inhibition ( Figure VI in the online-only Data Supplement). Moreover, overexpression of wild-type CYLD by adenoviral vectors did not affect necroptosis induced by Traf2 inactivation (Guo et al, unpublished data). These data suggest that CYLD is dispensable for necroptotic signaling in the setting of Traf2 inhibition.
Loss of Traf2 Promotes Necroptotic Signaling Through RIP1-RIP3-MLKL
To investigate the molecular mechanism by which Traf2 regulates necroptosis, we assessed whether Traf2 exerts its effects on necroptotic signaling by regulating the RIP1-RIP3-FADD necrosome formation. Inactivation of Traf2 by Ad-Traf2ΔR markedly promoted the interaction of RIP3 with RIP1 and FADD ( Figure 5A ). It has been suggested that the activated necrosome further engages MLKL, which oligomerizes and forms pores in the plasma membrane to initiate necroptotic cell death. 5, 6 Indeed, overexpression of Traf2ΔR also promoted the RIP1-RIP3-MLKL interaction induced by TNFα plus zVad ( Figure 5B ). Both endogenous Traf2 and Traf2ΔR mutant constitutively interact with MLKL, which was not altered by TNFα plus zVad ( Figure 5B ). Consistent with these data, ablation of RIP3 largely abolished HMGB1 release and necroptotic cell death triggered by Traf2 inhibition ( Figure 5C and 5D) . Ablation of RIP3 induced a mild increase in poly ADP-ribose polymerase cleavage and apoptotic cell death, which was blocked by zVad ( Figure 5C 
Ablation of RIP3 Rescues Pathological Cardiac Remodeling and Dysfunction in Traf2-Deficient Mice by Inhibiting Necroptosis In Vivo
To directly assess whether necroptosis contributes to cardiac cell death and pathological remodeling in Traf2-deficient mice in vivo, we generated cardiac-specific Traf2 knockout mice on a Ripk3 -/-background by crossing Traf2fl/fl-αMHC-Cre mice with Ripk3 -/-mice. Mice of different genotypes were confirmed by Western blot analysis of RIP3 and Traf2 expression in the heart ( Figure 6A ). Traf2fl/fl-αMHC-Cre mice on the Ripk3 +/+ background again developed severe contractile dysfunction, ventricular dilation, fibrosis, and hypertrophy ( Figure 6B-G) . This finding was associated with a marked increase in TUNEL-positive cells and plasma HMGB1, indicating elevated cardiac cell death (FigFigure 6 ORIGINAL RESEARCH ARTICLE ure 6H and I). Ablation of RIP3 largely reversed cardiac dysfunction, ventricular dilation, fibrosis, and hypertrophy in Traf2-deficient mice ( Figure 6B through 6G) . As expected, necrotic HMGB1 release was also abolished by RIP3 ablation ( Figure 6I ). It is intriguing that a mild increase of myocardial TUNEL staining was observed in Traf2-deficient mice on the Ripk3 -/-background compared with those on the Ripk3 +/+ background (Figure 6H) , suggesting that blockade of necroptosis was associated with a mild but significant increase in apoptosis. Moreover, ablation of RIP3 in cardiomyocytes also largely blocked cell death triggered by Traf2 deletion or inactivation ( Figure 5C and 5D, Figure IVC in the online-only Data Supplement). Taken together, these data reveal a critical role of myocardial necroptosis in the development of cardiac remodeling and dysfunction in Traf2-deficient mice. These results also validate RIP3 as a therapeutic target for heart failure because its ablation prevented pathological remodeling and heart failure in a mouse model of myocardial necroptosis induced by Traf2 ablation.
DISCUSSION
This study identified a critical role for Traf2 in myocardial survival and homeostasis by suppressing apoptosis and necroptosis. We showed that mice with cardiacspecific deletion of Traf2 developed pathological remodeling and heart failure through the induction of apoptotic and necroptotic cardiac cell death. We also provided genetic evidence identifying TNFR1-mediated, RIP3-dependent necroptosis in the pathogenesis of adverse cardiac remodeling and heart failure in Traf2-deficient mice. Our results support a model that ablation of Traf2 promotes TNFR1-mediated apoptotic and necroptotic signaling by a feed-forward mechanism through increased TNFα production ( Figure 6J ). Inhibition of Traf2 promotes necroptotic cell death through an NFκB-independent but RIP1-RIP3-MLKL-dependent mechanism ( Figure 6J) . Mechanistically, the adaptor protein TRADD is required in TNFα-induced necroptosis signaling triggered by Traf2 ablation. TAK1 acts downstream of Traf2 to regulate RIP1-mediated cell death complex formation and apoptosis/necroptosis.
We observed that Traf2 expression in the heart was significantly upregulated after pathological stress, including pressure overload and myocardial infarction. Other cellular stress, such as ultraviolet irradiation or translational inhibition, promotes Traf2 degradation. 38 Upregulation of Traf2 may represent an important cardioprotective mechanism on pathological stress. Indeed, it has been shown that mild overexpression of Traf2 provided protection against cardiac ischemic injury in transgenic mice. 18 However, cardiac-specific overexpression of high levels of Traf2 provoked adverse remodeling and heart failure. 19 Loss-of-function approaches may have greater biological relevance in elucidating the function of Traf2 signaling under physiological and pathological conditions. In this case, we showed that Traf2-deficient mice spontaneously developed dilated cardiomyopathy and heart failure with elevated cardiac cell death, thus validating a protective role of Traf2 in the heart. It has been shown that Traf2 and Traf5 play redundant roles in TNFα-induced NFκB activation. 39 However, unlike Traf2, deletion of Traf5 has no effects on TNFα-induced cardiac cell death (Chen Y et al, unpublished data) . Consistent with this finding, Traf5 -/-mice showed no obvious abnormalities in contrast to early lethality and tissue necrosis found in Traf2
-/-mice. 17, 40 Moreover, Traf3 -/-and Traf6 -/-mice showed distinct phenotypes compared with Traf2 -/-mice, indicating that Traf3 or Traf6 is not essential for cell survival. 41, 42 Thus, unlike other TRAF proteins, Traf2 is a dedicated regulator of cardiac cell survival/death and heart failure propensity.
We detected elevated plasma levels of TNFα in our cardiac-specific Traf2-deficient mice in vivo, consistent with a previous study using the global Traf2 knockout mice. 17 It has been shown that deletion of Traf2 led to increased TNFα production in L929 cells in vitro through an RIP1-and EDD-dependent mechanism. 43 Elevated TNFα production may represent an important feed-forward mechanism to promote cell death in Traf2-deficient cells in vivo and in vitro. Ablation of TNFR1 largely blocked adverse remodeling and heart failure in Traf2-deficient mice, further indicating that dysregulated TNFα signaling contributes to the pathological cardiac phenotype induced by Traf2 deficiency. Genetic deletion of TNFR1 did not fully rescue the pathological and functional defects in Traf2-deficient mice, suggesting the existence of additional TNFR1-independent mechanisms for cardiac cell death and disease development. It is possible that certain aspects of the pathological phenotype in Traf2-deficient mice could be mediated by other receptors (eg, DR3 and DR6) or other pathological drivers (eg, death ligands FasL or Apo2L/TRAIL).
We showed that Traf2 inhibition promoted TNFα-induced caspase activation and apoptosis, which were blocked by necrostatin-1, indicating the induction of RIP1-dependent apoptosis. The underlying mechanism probably involves RIP1-dependent induction of a caspase 8 activating complex consisting of RIP1-FADDcaspase 8. 33 Moreover, Traf2 inhibition also promoted necroptosis by inducing the RIP1-RIP3 necrosome. A significant decrease in RIP1 ubiquitination has been detected in the TNFR1 complex from Traf2 -/-cells on TNFα stimulation, 32 which was reversed by reconstituting with wild-type but not the RING domain-deleted form of Traf2. Decreased RIP1 ubiquitination, which promotes RIP1 activation and RIP1-RIP3 interaction, 4, 44 may account for the enhanced necrosome formation in Traf2-deficient cells. In line with this idea, we showed that overexpression of wild-type Traf2 inhibited, but Traf2 lacking RING domain (Traf2ΔR) promoted, TNFα-induced necroptosis in cardiomyocytes. However, Petersen et al 15 reported that transfection of Traf2 -/-MEFs with Traf2ΔR suppressed TNFα-induced necroptosis as effectively as reconstitution with wild-type Traf2. The reason for this obvious discrepancy is unclear, potentially caused by different cell lines used (cardiomyocytes versus MEFs) and different necroptosis-inducing conditions (TNF+zVad versus TNF+cylcoheximide+zVad). Nonetheless, we provided further evidence showing that the RING domain of Traf2 is critical in suppressing necrosome formation and necroptotic cell death through an RIP1-RIP3-MLKL-dependent mechanism. Although ablation of MLKL abrogated necroptosis in Traf2-deficient cells, we observed a constitutive interaction between MLKL and Traf2 (both wild-type and ΔR), which was not altered by necroptosis induced by TNFα plus zVAD (without cycloheximide). Thus, our data did not support the model proposed by Petersen et al, 15 where TNFα-induced necroptosis disrupts Traf2-MLKL interaction to promote RIP3-MLKL binding. Those effects observed by Petersen et al 15 could be caused by enhanced degradation Traf2 induced by TNFα and cycloheximide treatment and thus decreased Traf2-MLKL association. 38 Our data clearly indicate that Traf2-MLKL dissociation is dispensable for necroptotic signaling under certain necroptosis-inducing conditions (eg, without cycloheximide).
Ablation of Traf2 in the heart led to pathological myocardial remodeling and heart failure, which was largely rescued by genetic deletion of Ripk3, suggesting that unchecked myocardial necroptosis contributed significantly to the observed the pathological phenotype in Traf2-deficient mice. However, the rescue of the pathological and functional cardiac defects in Traf2-deficient mice by Ripk3 deletion was not complete. Actually, Ripk3 deletion largely blocked necroptosis but mildly increased apoptosis in the Traf2-deficient heart. These results highlight the complexity of cell death regulation involving the crosstalk between apoptotic and necroptotic pathways. Thus, therapies targeting both apoptotic and necroptotic pathways may prove to be more effective under certain pathological conditions.
Our results also defined the roles of several key components of the TNFR1 signaling pathway, including TRADD, TAK1, and CYLD, in necroptotic cell death in the setting of Traf2 inhibition. TRADD binds directly to the death domain of TNFR1 and transduces signals for both NFκB activation and apoptosis 11 by recruiting distinct signaling proteins of the TNFR1 complex, including Traf2, RIP1, or FADD.
11, 45 Here we showed that deletion of TRADD prevented TNFα-induced necrosome formation and necroptotic cell death in the setting of Traf2 inhibition, thus revealing an essential role of TRADD in necroptotic signaling. Deletion of TRADD may inhibit necroptotic signaling by preventing the recruitment of RIP1 to TNFR1 complex I. Indeed, it has been shown that recruitment of RIP1 to the TNFR1 complex is required for its ability to subsequently interact with FADD or RIP3 to induce cell death complexes. 46 These data indicate that TRADD, which acts upstream of Traf2, functions as a critical regulator of necroptotic signaling, in addition to its known role in NFκB activation and apoptosis. Moreover, Traf2 has been shown to regulate TAK1 activation through Lys63-linked ubiquitination in vitro and in vivo. 35 Inhibition of Traf2 may cause defective TAK1 signaling, which in turn promotes necroptosis. In supporting this finding, forced activation of TAK1 blocked necrosome formation and necroptotic cell death in Traf2-deficient cells, indicating that TAK1 exerts its anti-necroptotic effect by acting downstream of Traf2. CYLD has also been shown to function as a deubiquitinating enzyme for TAK1, RIP1, and Traf2. 15, 47, 48 CYLD and Traf2 may play opposite roles in regulating protein ubiquitination and necroptotic signaling. In contrast to a previous study, 15 our data showed that deletion of CYLD failed to block TNFα-induced necroptosis in Traf2-deficient cells. By comparison, we observed that CYLD is required for RIP1 kinase activation and subsequent necrosome formation in the setting of TAK1 inhibition. 33 Therefore, CYLD does not seem to be critical in transducing necroptosis in the setting of Traf2 inhibition, although it is required for necroptotic signaling under certain conditions.
In conclusion, our results demonstrated that Traf2 functions as a critical prosurvival factor in the heart by suppressing both myocardial apoptosis and necroptosis. We provide novel evidence that inhibition of necroptosis by Traf2 is critical for myocardial homeostasis and the prevention of pathological remodeling and heart failure progression. Our data also identify several signaling proteins in the TNFR1 pathway (eg, TRADD, Traf2, and TAK1) as critical regulators of necroptosis in cardiac myocytes. Targeting key components of the necroptotic signaling may represent a valid therapeutic strategy for pathological cardiac remodeling and heart failure.
